Webbläsaren som du använder stöds inte av denna webbplats. Alla versioner av Internet Explorer stöds inte längre, av oss eller Microsoft (läs mer här: * https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Var god och använd en modern webbläsare för att ta del av denna webbplats, som t.ex. nyaste versioner av Edge, Chrome, Firefox eller Safari osv.

Default user image.

Tommy Knöös

Sjukhusfysiker

Default user image.

A Phase I/II Evaluation of Metoclopramide as a Radiosensitiser in Patients with Inoperable Squamous Cell Carcinoma of the Lung

Författare

  • Elisabeth Kjellén
  • Ronald Pero
  • Eva Brun
  • Sven-Börje Ewers
  • Olof Jarlman
  • Tommy Knöös
  • Per Malmström
  • Jan Tennvall
  • Dick Killander
  • A. Olsson
  • Y. Sheng
  • Johan Wennerberg
Visa allt

Summary, in English

The feasibility of administering metoclopramide (MCA) as a radiosensitizer has been evaluated in 23 patients with a pathological or cytological diagnosis of a squamous cell carcinoma of the lung, clinically evaluated as inoperable. All patients received 40-60 Gy radiotherapy fractionated into 1.8 Gy fractions 5 times per week (Monday-Friday). Two MCA treatment regimens were used: (i) MCA at 2 mg/kg administered by intravenous infusion 1-2 h prior to radiotherapy 3 times per week (Monday, Wednesday, Friday); and (ii) MCA at 1 mg/kg administered by intravenous infusion 1-2 h prior to radiotherapy 5 times per week (Monday-Friday). 11 of the 23 patients treated with radiotherapy and MCA had none to mild pneumonitis or fibrosis and another 8 of the 23 had moderate levels. No patient had their therapy interrupted due to radiation-related side-effects. The MCA-related side-effects were as expected, i.e. 78% of the patients experienced sedation/tiredness and 48% expressed restlessness/anxiety symptoms. Both the total dose and serum levels of MCA were significantly associated to the MCA side-effect profile. Tumour response, duration of tumour response and survival were significantly positively correlated to the total and weekly doses of MCA administered to the patients during their radiotherapy treatment. These favourable phase II data have justified the initiation of a phase II/III randomised multicentred trial being carried out in Europe to evaluate MCA as a radiosensitiser.

Avdelning/ar

  • Bröstcancer-genetik
  • Immunology
  • Nuklearmedicin, Malmö
  • Medicinsk strålningsfysik, Lund
  • Öron-, näs- och halssjukdomar, Lund

Publiceringsår

1995

Språk

Engelska

Sidor

2196-2202

Publikation/Tidskrift/Serie

European Journal of Cancer

Volym

31

Issue

13-14

Dokumenttyp

Artikel i tidskrift

Förlag

Elsevier

Ämne

  • Immunology in the medical area
  • Radiology, Nuclear Medicine and Medical Imaging
  • Otorhinolaryngology
  • Cancer and Oncology

Nyckelord

  • metoclopramide
  • radiosensitiser
  • lung cancer
  • phase I/II trial
  • squamous cell carcinoma

Status

Published

Forskningsgrupp

  • Immunology
  • Nuclear medicine, Malmö

ISBN/ISSN/Övrigt

  • ISSN: 1879-0852